Adherence to national guidelines for lipid management and use of statins;L'application des recommandations médicales lors de la prescription de statines

Revue d'Epidemiologie et de Sante Publique

Volumn 50, Issue 5, 2002, Pages 463-473

  Chevalier, C ^a   Giral, P ^b   Chinaud, F ^a   Carzon, M ^a   Gartenlaub, D ^a   Blanchon, B ^c   Trutt, B ^a  

^a Caisse Nationale d'Assurance Maladie des Travailleurs Salaries   (France)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^c NONE

Author keywords

Coronay heart disease prevention; Guidelines; LDL cholesterol; Statins

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ALGORITHM; ARTICLE; CARDIOVASCULAR RISK; CLINICAL PRACTICE; CONTROLLED STUDY; DATA BASE; DIET; DRUG EFFICACY; DRUG USE; FOLLOW UP; FRANCE; HEALTH INSURANCE; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; PRACTICE GUIDELINE; REIMBURSEMENT;

ALGORITHMS; CHOLESTEROL, LDL; DECISION TREES; DIET, FAT-RESTRICTED; DRUG UTILIZATION REVIEW; FEMALE; FRANCE; GUIDELINE ADHERENCE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; MALE; MIDDLE AGED; NEEDS ASSESSMENT; PRACTICE GUIDELINES; PRESCRIPTIONS, DRUG; RISK FACTORS;

EID: 0036816586     PISSN: 03987620     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Gould AL, Rossouw JE, Santanello NC, Heyse JF, Furberg CD. Cholesterol reduction yields clinical benefit impact of statin trials. Circulation 1998; 97: 946-52.
2. Grundy SM. Statin trials and goals of cholesterol-lowering therapy. Circulation 1998; 97: 1436-39.
3. Sacks FM., Pfeffer MA., Moyle LA, Rouleau JL, Rutherford JD, Cole TG et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Eng J Med 1996; 335: 1001-9.
4. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N Eng J Med 1998; 339: 1349-57.
5. Scandinavian Simvastatin Survival Study group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383-9.
6. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, Macfarlone P et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Eng J Med 1995; 333: 1301-7.
7. Urcam Ile-de-France. Eléments de diagnostic sanitaire régional en Ile de France - septembre 2000.
8. Agence Nationale pour le Développement et l'Évaluation Médicale (ANDEM). Hypolipidémiants. Concours Méd 1996; 41: 58-72.
9. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972; 18: 499-502.
10. Planella T, Cortes M, Martinez-Bru C, Gonzalez-Sastre F, Ordonez-Llanos J. Calculation of LDL-cholesterol by using apolipoprotein B for classification of nonchylomicronemic dyslipemia. Clin Chem 1972; 43: 808-15.
11. Urcam Ile-de-France. La prescription des équivalents thérapeutiques et des génériques en Ile-de-France en décembre 1996, Paris.
12. McBride P, Schrott HG, Plane MB, Underbakke G, Brown R. Primary care practice adherence to national cholesterol education program guidelines for patients with coronary heart disease. Arch Intern Med 1998; 158: 1238-44.
13. EUROASPIRE Study Group. EUROASPIRE. A European Society of Cardiology survey of secondary prevention of coronary heart disease, principal results. Eur Heart 1997; 18: 1569-82.
14. EUROASPIRE I and II Group. Clinical reality of coronary prevention guidelines: A comparison of EUROASPIRE I and II in nine countries. Lancet 2001; 357: 995-1001.
15. Bain NSC, Foster K, Grimshaw J, MacLeod TN. Can audit of a local protocol for the management of lipid disorders effect and detect a change in clinical practice. Health Bull 1997; 55: 94-102.
16. Van Der Weijden T, Grol RPTM, Schouten BJ, Knotmerus JA. Barriers to working according to cholesterol guidelines. A randomized controlled trial on implementation of national guidelines in 20 general practices. Eur J Public Health 1998; 8: 113-8.
17. Abookire SA, Karson AS, Fiskio J, Bates DW. Use and monitoring of "Statin" lipid-lowering drugs compared with guidelines. Arch Intern Med 2001; 161: 53-8.
18. Tang JL, Armitage JM, Lancaster T, Silagy CA, Fowler GH, Neil HAW. Systematic review of dietary intervention trials to lower blood total cholesterol in free-living subjects. Brit Med J 1998; 316: 1213-20.
19. Hooper L, Summerbell CD, Higgins JPT, Thompson RL, Capps NE, Smith GD et al. Dietary fat intake and prevention of cardiovascular disease: Systematic review. Brit Med J 2001; 322: 757-63.
20. De Lorgeril M, Salen P, Martin JL, Maujaud I, Delaye J, Mamelle N et al. Mediterranean diet, traditional risk factors and the rate of cardiovascular complications after myocardial infarction. Final report of the Lyon diet heart study. Circulation 1999; 99: 779-85.
21. Agence Nationale d'Accréditation et d'Évaluation en Santé. Efficacité des Méthodes de Mise en Oeuvre des Recommandations Médicales. Paris, ANAES, 2000.
22. Cabana MD, Rand CS, Powe NR, Wu AW, Wilson MA, Alboud PAC, et al. Why don't physicians follow clinical practice guidelines? A framework for improvement. JAMA 1999; 282: 1458-65.
23. Agence Nationale d'Accréditation et d'Évaluation en Santé. Recommandations et Références Professionnelles. Modalités de Dépistage et Diagnostic Biologique des Dyslipidémies en Prévention Primaire. Paris, ANAES, 2000.
24. Agence Française de Sécurité Sanitaire des Produits de Santé. La Prise en Charge Thérapeutique du Patient Dyslipidémique. Paris, AFSSAPS, 2000.